The Company held its Annual General Meeting at its offices in Oxford on 20th November 2018 and is pleased to announce that all resolutions put to shareholders were passed.
Please click here to read in full....
Physiomics plc is pleased to announce that it will be attending the 30th EORTC-NCI-AACR SYMPOSIUM in Dublin 13-16 November 2018. The European Organisation for
Research and Treatment of Cancer (“EORTC”) acts as a hub for a network of over 930 institutions in 30 countries focused on translational and clinical cancer research.
The Symposium is co-hosted by EORTC, the National Cancer Institute (NCI) and the American Association for...
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has today posted to shareholders
its Annual Report for the financial year ended 30th June 2018 and
a Circular in relation to its forthcoming Annual General Meeting
Please click here to read in full....
Dr Jim Millen, CEO of Physiomics, talks to Proactive Investors’ Andrew Scott about recent successes and the company’s future direction.
Please click here to watch video....
Chairman and Chief Executive Officer’s Statement
Introduction
We are very pleased to report on a year when we generated the highest total income in the Company’s history. Having secured the agreement with Merck KGaA in November 2017, we were able to turn our attention to our pipeline and, leveraging the publicity generated by the Merck deal we converted two large pharmaceutical clients and a biotech client in...
Physiomics is delighted to announce that it has been awarded a contract by a new European biotech client. The value of the contract is £55k and it is expected to complete in this calendar year.
Click here to read in full....
Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm that based on its current unaudited accounts at 20th June, it is trading ahead of market expectations for its full financial year ending 30th June 2018.
Click here to read in full...
Dr Jim Millen, CEO of Physiomics, talks to Proactive Investors’ Andrew Scott about recent successes and the company’s future direction.
Please click here to watch video....
Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is delighted to announce that it has been awarded a contract by a new UK based biotech client. The value of the contract is £48k and it is expected to complete in this calendar year.
Click here to read in full....